The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2. It’s the first FDA-approved therapy for this target.
The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series of clinical and financial setbacks that left much of the biotech’s fortunes resting on its lead antibody drug.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The Food and Drug Administration has provided a Breakthrough Device Designation for AI Medical Service's' machine learning algorithm that has the ability to analyze endoscopy images for potential diagnosis of gastric cancer.
In its second Amgen partnership this year, NantWorks - billionaire Patrick Soon-Shiong's sprawling healthcare company - is working on a Phase 2 small molecule drug that treates gastric cancer.